Blue Earth Diagnostics Ltd

🇳🇴Norway

Country: 🇳🇴Norway

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Intrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

Phase 4

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: Flotufolastat (18F)
Drug: piflufolastat (18F)

First Posted Date: 2024-09-19

Last Posted Date: 2025-06-04

Lead Sponsor: Blue Earth Diagnostics

Target Recruit Count: 52

Registration Number: NCT06604442

Locations: 🇺🇸
Mayo Clinic, Jacksonville, Florida, United States
🇺🇸
XCancer Omaha/Urology Cancer Center, Omaha, Nebraska, United States
🇺🇸
City of Hope Medical Center, Duarte, California, United States

and more 5 locations

Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases

Phase 3

Completed

Conditions: Brain Metastases

Interventions: Drug: 18F fluciclovine

First Posted Date: 2020-06-01

Last Posted Date: 2023-07-12

Lead Sponsor: Blue Earth Diagnostics

Target Recruit Count: 151

Registration Number: NCT04410133

Locations: 🇺🇸
West Virgina University Cancer Institute, Morgantown, West Virginia, United States
🇺🇸
Medical College of Georgia, Augusta University, Augusta, Georgia, United States
🇺🇸
John Wayne Cancer Institute at Providence St. John's Health Center, Santa Monica, California, United States

and more 16 locations

Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)

Phase 2

Completed

Conditions: Brain Metastases

Interventions: Drug: 18F fluciclovine

First Posted Date: 2020-06-01

Last Posted Date: 2023-08-01

Lead Sponsor: Blue Earth Diagnostics

Target Recruit Count: 23

Registration Number: NCT04410367

Locations: 🇺🇸
University Hospital Cleveland, Cleveland, Ohio, United States
🇺🇸
University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
🇺🇸
Miami Cancer Institute, Miami, Florida, United States

and more 6 locations

Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: rhPSMA-7.3 (18F) Injection
Diagnostic Test: Positron Emission Tomography scan

First Posted Date: 2019-12-05

Last Posted Date: 2025-02-26

Lead Sponsor: Blue Earth Diagnostics

Target Recruit Count: 356

Registration Number: NCT04186819

Locations: 🇺🇸
Tower Urology, Los Angeles, California, United States
🇺🇸
John Wayne Cancer Institute, Santa Monica, California, United States
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States

and more 31 locations

Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: rhPSMA-7.3 (18F) Injection
Diagnostic Test: Positron emission tomography scan

First Posted Date: 2019-12-05

Last Posted Date: 2025-02-26

Lead Sponsor: Blue Earth Diagnostics

Target Recruit Count: 391

Registration Number: NCT04186845

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇳🇱
Maxima MC, Veldhoven, Netherlands

and more 25 locations

Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: rhPSMA-7.3 (18F) Injection

First Posted Date: 2019-06-24

Last Posted Date: 2020-05-18

Lead Sponsor: Blue Earth Diagnostics

Target Recruit Count: 16

Registration Number: NCT03995888

Locations: 🇫🇮
Clinical Research Services Turku - CRST Oy, Turku, Finland

18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: 18F-fluciclovine PET CT

First Posted Date: 2016-02-11

Last Posted Date: 2019-01-28

Lead Sponsor: Blue Earth Diagnostics

Target Recruit Count: 221

Registration Number: NCT02680041

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 14 locations

Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer

Phase 3

Completed

Conditions: Cancer of the Prostate

Interventions: Drug: 18F-Fluciclovine PET CT

First Posted Date: 2015-10-19

Last Posted Date: 2019-10-07

Lead Sponsor: Blue Earth Diagnostics

Target Recruit Count: 104

Registration Number: NCT02578940

Locations: 🇬🇧
Royal Marsden Hospital, Sutton, Surrey, United Kingdom
🇬🇧
Mount Vernon Cancer Centre, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom
🇬🇧
Churchill Hospital, Oxford, Oxfordshire, United Kingdom

and more 4 locations

Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)

Completed

Conditions: Prostatic Neoplasms

First Posted Date: 2015-05-14

Last Posted Date: 2018-12-19

Lead Sponsor: Blue Earth Diagnostics

Target Recruit Count: 714

Registration Number: NCT02443571

Locations: 🇮🇹
University Hospital Sant'Orsola Malpighi, Bologna, Italy
🇳🇴
Aleris Kreftsenter, Oslo, Norway
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States

and more 1 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy